How logical is Globe’s claim of rolling out a vaccine in December?
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
TUESDAY, MAY 24, 2022
TUESDAY, MAY 24, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
How logical is Globe’s claim of rolling out a vaccine in December?

Coronavirus chronicle

Tawsia Tajmim
06 October, 2020, 10:40 pm
Last modified: 07 October, 2020, 12:21 am

Related News

  • China Junshi's potential Covid drug shows promise in small trial
  • Indonesia to drop outdoor mask mandate as Covid-19 infections drop
  • N Korean leader slams officials' 'immaturity' in response to Covid outbreak
  • Shanghai achieves 'zero Covid' status but normal life is weeks away
  • N Korea mobilises army, steps up tracing amid Covid wave

How logical is Globe’s claim of rolling out a vaccine in December?

Globe Biotech’s CEO says the three-stage trials will take five months

Tawsia Tajmim
06 October, 2020, 10:40 pm
Last modified: 07 October, 2020, 12:21 am
The clinical trial is very lengthy, critical and important as well. Photo: Reuters/Thomas Peter/Files
The clinical trial is very lengthy, critical and important as well. Photo: Reuters/Thomas Peter/Files

Health and vaccine experts are surprised by Globe Biotech's claim that it can bring its Covid-19 vaccine to the market by December this year if it gets the government's help.

The Globe Biotech Ltd has neither applied to the Bangladesh Medical Research Council (BMRC) yet to conduct clinical trials of its vaccine candidate nor appointed any contract research organisation (CRO).

Yet, the local pharmaceutical company claims that it can roll out its potential Covid-19 vaccine on the market within 2-3 months if they get the necessary support.

At a press briefing on Monday, the company said they have successfully completed animal trials of its coronavirus vaccine named BNCOVID.

They hope that they will be able to go into production after human trials if the government provides support.

Prof Sayedur Rahman, chairman at the Bangladesh Pharmacological Society, told The Business Standard, "It would take 10 years on an average to bring a vaccine to the market before the Covid-19 pandemic hit. This is for the first time, the production time has been reduced to 18 to 24 months."

On 2 July, Globe Biotech first officially announced it had developed a Covid-19 vaccine. It would take five to six months to bring its vaccine to the market as per its claim.

"Do they have a magic wand? Will they make a vaccine by December just by the touch of it?" said Dr Muniruddin Ahmed, a professor at the Department of Clinical Pharmacy and Pharmacology of the University of Dhaka.

"It is October now. How will it be possible to complete three stage trials of the vaccine, data collection and analyses, plus peer review in an international journal only in two months? How can this claim be termed scientifically correct?" he added.

The clinical trial is very lengthy, critical and important as well, he added. 

"We hope the Globe Biotech's initiative to develop a [novel] coronavirus vaccine sees success. But it is not possible to do so through exaggeration and unrealistic talks," he continued.    

Harunur Rashid, chairman of Globe Pharmaceuticals Limited, at a press conference on Monday, said "We will be able to launch the vaccine between December and January. We are ready to prepare the doses. We have completed everything on our part. Now, we are waiting for the overall cooperation of the BMRC and the Directorate General of Drug Administration, particularly of the government."

Dr Kakon Nag, Globe Biotech's chief executive officer, said "We are now working to appoint a CRO and make a protocol for clinical trials of our vaccine. After the appointment of the CRO, we will apply to the BMRC for a permission to conduct clinical trials."

"When we go for the clinical trials depends on the government's decision. The three-stage trials will take five months," he pointed out.

When asked about how it is possible to bring the vaccine to the market if it takes five more months to complete the remaining job, Kakon Nag told The Business Standard, "If we get support from the government, like what the United States' Moderna has got from their government, our vaccine will hit the market in December or January." 

"We have completed our job. We have developed the vaccine and done whatever is required from scientific safety to efficacy," he added. 

Dr M Mushtaq Hussain, adviser to the Institute of Epidemiology, Disease Control, told The Business Standard that there is an opportunity to complete administrative work quickly. But it is necessary to wait for a specific time to see how the vaccine works in the human body. There is no shortcut."

According to the United States Centres for Disease Control and Prevention, the general stages of the development cycle of a vaccine are exploratory stage, pre-clinical stage, clinical development, regulatory review and approval, manufacturing, and quality control. 

Clinical development is a three-phase process. During phase I, small groups of people receive the trial vaccine. In phase II, the clinical study is expanded and the vaccine is given to people who have characteristics – such as age and physical health – similar to those for whom the new vaccine is intended. In phase III, the vaccine is given to thousands of people and tested for efficacy and safety.

Medical Scientist Professor Liakot Ali told The Business Standard that each phase of the trials and other formalities must follow their rules and timing.    

"There is no scope for showing-off or illogical claims here," he added.     

Kakon Nag claimed that they have published the animal trial reports of their potential vaccine to the international platform, biorxive.org.

Regarding this, Dr M Mushtaq Hussain said peer-reviewed articles for publication in any scientific journal are authentic.

He said, "They are only one step ahead as they submitted the article. However, it has yet to be published in any scientific journal."

BMRC Director Dr Mahmood-uz-Jahan told The Business Standard that it was too early to comment on the potential vaccine developed by Globe Biotech since they had yet to receive the documents.    

"We will give the approval after verifying the papers. We will maintain all the required procedures," said Dr Mahmood.

Top News

Globe / Covid / Coronavirus

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Corporates go cashless…tax cut on cards
    Corporates go cashless…tax cut on cards
  • Rising revenue collection a false dawn, economists say
    Rising revenue collection a false dawn, economists say
  • Why we must resist geoeconomic fragmentation—and how
    Why we must resist geoeconomic fragmentation—and how

MOST VIEWED

  • A medical worker takes a swab sample from a person for a nucleic acid test at a makeshift testing site, amid the coronavirus disease (Covid-19) outbreak, in Beijing, China May 23, 2022. REUTERS/Tingshu Wang
    Beijing urges millions to keep working from home amid Covid outbreak menace
  • Picture: PTI
    Saudi Arabia bans travel to India, 15 other countries over Covid outbreaks
  • A person in personal protective equipment (PPE) walks a dog at a resident community, as the second stage of a two-stage lockdown has been launched to curb the spread of the coronavirus disease (Covid-19) in Shanghai, China April 3, 2022. REUTERS/Aly Song
    Shanghai reopens some public transport, still on high Covid alert
  • Workers in protective suit spray disinfectant at a community, during the lockdown to curb the spread of the coronavirus disease (COVID-19) in Shanghai, China, April 5, 2022. REUTERS/Aly Song
    Dynamic zero-Covid approach: China's choice to safeguard lives, underpin growth
  • People wearing protective face masks walk on a street, following new cases of the coronavirus disease (Covid-19), in Shanghai, China August 25, 2021. REUTERS/Aly Song
    Shanghai district to require all shops to shut, residents to stay home
  • Photo: Courtesy
    Covax calls for urgent action to close vaccine equity gap

Related News

  • China Junshi's potential Covid drug shows promise in small trial
  • Indonesia to drop outdoor mask mandate as Covid-19 infections drop
  • N Korean leader slams officials' 'immaturity' in response to Covid outbreak
  • Shanghai achieves 'zero Covid' status but normal life is weeks away
  • N Korea mobilises army, steps up tracing amid Covid wave

Features

Musk is denying the sexual harassment allegation that surfaced this week. Photo: Bloomberg

Elon Musk’s crazily banal week 

15h | Panorama
Asus Zenbook 14 Flip OLED: A touch of brilliance to your life

Asus Zenbook 14 Flip OLED: A touch of brilliance to your life

18h | Brands
Keep your phone by your side with this armband

Keep your phone by your side with this armband

16h | Brands
Are Focallure gel masks worth the hype?

Are Focallure gel masks worth the hype?

17h | Brands

More Videos from TBS

Why are Duranta TV shows popular?

Why are Duranta TV shows popular?

10h | Videos
Donbas is hell, says Zelenskiy

Donbas is hell, says Zelenskiy

11h | Videos
Threat of Monkeypox on the horizon

Threat of Monkeypox on the horizon

12h | Videos
Mosque of Mughal period in Gazipur

Mosque of Mughal period in Gazipur

12h | Videos

Most Read

1
Tk100 for bike, Tk2,400 for bus to cross Padma Bridge
Bangladesh

Tk100 for bike, Tk2,400 for bus to cross Padma Bridge

2
A packet of US five-dollar bills is inspected at the Bureau of Engraving and Printing in Washington March 26, 2015. REUTERS/Gary Cameron
Banking

Dollar hits Tk100 mark in open market

3
Bangladesh at risk of losing ownership of Banglar Samriddhi
Bangladesh

Bangladesh at risk of losing ownership of Banglar Samriddhi

4
PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire
Crime

PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire

5
BSEC launches probe against Abul Khayer Hero and allies
Stocks

BSEC launches probe against Abul Khayer Hero and allies

6
The reception is a volumetric box-shaped room that has two glass walls on both the front and back ends and the other two walls are adorned with interior plants, wood and aluminium screens. Photo: Noor-A-Alam
Habitat

The United House: Living and working inside nature

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab